Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31009431 | 0.83 | MAPT (0.35) | MAPTLMNAHTTBLMMEN1 | |
| SCHEMBL1171844 | 0.83 | MAPT (0.35) | MAPTLMNAHTTBLMMEN1 | |
| SCHEMBL3333977 | 0.75 | LMNA (0.42) | MAPTLMNAHTTBLMMEN1 | |
| SCHEMBL13534207 | 0.75 | LMNA (0.42) | MAPTLMNAHTTBLMGAA | |
| SCHEMBL31038320 | 0.75 | LMNA (0.42) | MAPTLMNAHTTBLMMEN1 | |
| SCHEMBL15988846 | 0.75 | ALOX15 (0.50) | MAPTLMNAHTTBLMGAA | |
| SCHEMBL16595637 | 0.75 | LMNA (0.42) | MAPTLMNAHTTBLMMEN1 | |
| SCHEMBL4167422 | 0.75 | MAPT (0.39) | MAPTGAATDP1LARS1AHR | |
| SCHEMBL419983 | 0.75 | PARP1 (0.36) | MAPTGAALARS1KDM4EALDH1A1 | |
| SCHEMBL30200188 | 0.75 | ALOX15 (0.50) | MAPTLMNAHTTBLMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3600307-B1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIV HOUSTON SYSTEM (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MAPT 2871/4885LMNA 1297/4885HTT 1455/4885 |
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | RIPK2, RIPK1, NOD2 | MAPT 3141/4885LMNA 2304/4885HTT 1641/4885 |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | MAPT 2057/4885LMNA 624/4885HTT 1482/4885 |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | RIPK2, RIPK1, NOD2 | MAPT 3141/4885LMNA 2304/4885HTT 1641/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | MAPT 1924/4885LMNA 589/4885HTT 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.